Okairos’ growing pipeline of modified adenovirus vectors offers numerous opportunities for co-development of our vaccine candidates in multiple therapeutic areas, including hepatitis C, flu, respiratory syncytial virus malaria and cancer.
Our proprietary adenovirus platform also provides the basis for collaborations for the development of other vaccines.
We intend to bring our core vaccine candidates through to the completion of Phase II proof-of-concept trials, and will seek partnerships to support Phase III trials and market our vaccines worldwide. Selected vaccine candidates outside our core areas may be out-licensed at an earlier stage of development.
Biopharmaceutical companies with a focus on infectious diseases and the clinical development of active immunotherapies can contact our Chief Operating Officer Tom Woiwode email@example.com to explore potential partnerships.